Introduction
============

Immune system plays an important role in brain development and function, by positively modulating, under normal conditions, neural plasticity, neurogenesis, and learning and memory \[[@R1]\]. This role is accomplished through intricate mechanisms involving non-neuronal brain cells with immune functions, peripheral immune cells, neurons, and neural precursor cells \[[@R1]\]. Complex interactions among neuronal and non-neuronal cells mediated by neuro- transmitters, inflammatory cytokines, and growth factors mainly underlie these mechanisms \[[@R1]\]. Following the initial discovery of increased levels of circulating inflammatory cytokines in depression \[[@R2]-[@R4]\], evidence implicating immune system alterations in the disease has increasingly been obtained in the last twenty five years \[[@R5]-[@R14]\]. Both environmental and genetic factors may potentially contribute to the development of depression *via* affecting immune and inflammatory processes \[[@R15]\]. Medical illness, obesity, childhood trauma, stress, poor sleep, and gastrointestinal inflammation are examples of environmental factors that are considered to raise the susceptibility to depression by causing chronic exposure to elevated levels of inflammatory cytokines \[[@R15]\]. With regard to genetic factors, hypothesis driven candidate gene analyses and unbiased genome-wide studies have provided evidence for the association of several immune and inflammation related genes in depression \[[@R16]-[@R18]\]. As hypothesis free genome level analyses provide powerful means to statistically identify potential molecular pathways underlying etiology and pathophysiology of complex disorders, this article aims at overviewing the available genomic, transcriptomic and proteomic data in depression to specifically examine if the immune and inflammation hypothesis of the disease is supported. Besides human studies, an overview of transcriptomic analyses in animal models of depression and antidepressant treatment is also provided in order to investigate whether preclinical data is consistent with the said hypothesis.

Genome-wide association studies in human **depression**
=======================================================

With several genome-wide association studies in depression reported \[[@R19]\], a recent large scale pathway based analysis of single nucleotide polymorphisms (SNPs) underlying genetic risk has notably identified statistically significant association of immune pathway, besides neuronal signaling, synaptic and histone methylation pathways, in major depressive disorder (MDD), as also in bipolar disorder

and schizophrenia \[[@R20]\]. This analysis of association data from over 60,000 subjects, encompassing the three neuropsychiatric diseases mentiond above, is based on the observation that loci showing nominal but not genome-wide significance in original studies may considerably contribute to disease susceptibility. It reports a total of 159 depression associated genes as overrepresenting the aforementioned pathways \[[@R20]\]. In order to gain further insight into immune and inflammation hypothesis of depression, overrepresentation of biological process categories in these genes was reexamined by this author using gene ontology tool \[[@R21]\]. Interestingly, several immune and inflammation related processes, besides others, showed enrichment at nominal 0.05 p value cut-off. Some of the processes with a large number of genome-wide association genes are listed here (Table **1**). It is apparent from this list that depression associated genes relate to both development as well as functioning of the immune system. Other significant processes identified in this secondary analysis include positive regulation of chronic inflammatory response, negative regulation of cytokine secretion involved in immune response, regulation of B cell mediated immunity, activation of immune response, activation of innate immune response etc.

Whole genome sequencing in human depression
===========================================

Besides SNP based genome-wide association studies, a low coverage whole genome sequencing analysis has also been carried out in depression \[[@R22]\]. This study comprises sequencing of over 5,000 subjects with recurrent MDD and a matching number of subjects that were screened to exclude MDD as the discovery cohort, and replication of signals in an independent sample of over 3,000 participants each. The analysis led to the identification of two risk loci at genome-wide significance, one near *SIRT1*, the gene encoding a member of the sirtuin family of proteins, and the other in an

intron of *LHPP*, the gene encoding a phosphatase \[[@R22]\]. The *SIRT1* association was further supported by analysis of another 4,000 subjects with melancholia, a severe MDD subtype. Interestingly, *SIRT1* is categorized in gene ontology under, besides others, regulation of adaptive immune response, negative regulation of I-kappaB kinase/NF-kappaB signaling, and negative regulation of NF-kappaB trans- cription factor activity. This further supports the genetic evidence implicating immune and inflammatory pathways in depression.

Transcriptomic analyses in human depression
===========================================

Several transcriptome profiling of postmortem brain samples have been reported in depression (Table **2**). Unlike association of genetic variations, gene expression alterations in a disease may potentially be confounded by downstream effects of etiological factors and therapeutic interventions \[[@R20]\]. Moreover, the transcriptomic studies that have been reported in depression represent a diversity of tissue samples from brain, a highly heterogeneous organ, with different drug exposure history. Despite these complexities in the samples analyzed, it is notable that several genes have  been found as differentially expressed in two or more studies (Fig. **[1](#F1){ref-type="fig"}**). Most interestingly, these genes also show, like genome-wide association genes mentioned above, significant enrichment for immune and inflammation related processes, besides others, in gene ontology analysis. Examples of the enriched processes with numerous differentially expressed genes are tabulated here (Table **[3](#T3){ref-type="table"}**). It is notable that a majority of these processes were also identified in genome-wide association (Table **[1](#T1){ref-type="table"}**) analysis in human depression. Additional overrepresented processes include cytokine production involved in immune response, innate immune response activating cell surface receptor signaling pathway, mast cell mediated immunity etc. Although gene expression studies in depression have also been conducted on peripheral

blood, these are not reviewed here as the present objective is to specifically examine direct pathophysiological evidence obtained from studies on brain samples. These studies are nonetheless discussed later in the article.

Proteomic analyses in human depression
======================================

Proteomic profiling of brain samples has also been reported in depression (Table **[4](#T4){ref-type="table"}**). Notably, in a small set of proteins that show differential expression in more than one study (Fig. **[2](#F2){ref-type="fig"}**), there is one, *APOE*, that is categorized under negative regulation of inflammatory response in gene ontology \[[@R21]\]. In enrichment analysis mentioned above, this process is found to be significantly overrepresented in the set of differentially expressed proteins. Cumulatively, genetic association, and mRNA and protein expression analyses, though diverse, together support immune and inflammation hypothesis of depression. Although protemic profiling of peripheral blood has also been reported in depression, the same is not reviewed here because, as mentioned above, the present focus is to examine direct pathophysiological evidence resulting from the analysis of brain samples. Nevertheless, these proteomic studies are discussed in the later section of the article.

Transcriptomic analyses of anti- depressant effects in animal models
====================================================================

Numbers in the parentheses indicate references in Table **[2](#T2){ref-type="table"}**, provided for genes at their first column-wise occurrence.

Transcriptomic effects of antidepressant drugs in rats and mice have also been investigated by several groups (Table **[5](#T5){ref-type="table"}**). Although these studies differ with respect to animal model, antidepressant drug and brain region investigated, a combined analysis is presented here because the number of published studies is not sufficient to support individual model, drug and region specific examination of transcriptomic convergence. Interestingly, genes showing differential expression in two or more studies (Fig. **[3](#F3){ref-type="fig"}**) are found to overrepresent, immune and inflammation related in gene ontology based enrichment analysis mentioned above. Some of the overrepresented processes with several differentially expressed genes are listed here (Table **[6](#T6){ref-type="table"}**). It is interesting to note that a majority of these processes, or all of them, were also identified in genome-wide association (Table **[1](#T1){ref-type="table"}**) and transcriptomic (Table **[3](#T3){ref-type="table"}**) analysis in human depression. Other enriched processes include adaptive immune response, regulation of acute inflammatory response, regulation of innate immune response etc.

Transcriptomic analyses in a rodent model of depression
=======================================================

Finally, transcriptomic analyses in chronic social defeat stress in rodents, an established model of depression, is considered. A review of findings reported in this model (Table **[7](#T7){ref-type="table"}**) shows several genes that are differentially expressed in two or more studies (Fig. **[4](#F4){ref-type="fig"}**). Notably, two of these genes, *APOD* and *JUN*, are related to immunity and inflammation. Whereas the former is categorized under negative regulation of cytokine production involved in inflammatory response, and negative regulation of T cell migration, the latter is under innate immune response, response to cytokine, and toll-like receptor signaling pathway. Together, animal model studies, despite their diversity, seem consistent with the immune and inflammation hypothesis of depression. Besides chronic social defeat stress, other animal models of depression also exist. It will be interesting to review gene expression evidence obtained in these models in future.

Gene level convergence among reviewed **studies**
=================================================

It is interesting to note that the lone common gene between genome-wide association (Table **[1](#T1){ref-type="table"}**) and trans- criptomic (Fig. **[1](#F1){ref-type="fig"}**) analysis in human depression, *ITPR1*, which encodes an intracellular receptor for inositol 1,4,5-trisphosphate, is related to, besides immunity and inflammation, several brain development and function related pathways relevant to depression. For example, the brain development related pathways include signaling by FGFR3, the gene encoding which, interestingly, is found to be differentially expressed in human depression (Fig. **[1](#F1){ref-type="fig"}**), and NGF signaling *via* TRKA from the plasma membrane \[[@R50]\]. The brain function related pathways include, besides others, dopaminergic synapse and serotonergic synapse which are involved in learning and memory, motivation and reward, emotion, sleep and pain, and in pathological states like abnormal mood and cognition \[[@R50]\]. Remarkably, it has been reported that mice carrying cerebral knockdown of ITPR1 show an antidepressant behaviour \[[@R51]\].

Discussion
==========

The present review of genomic, transcriptomic and proteomic studies shows that human depression associated genetic variations, and differentially expressed mRNAs and proteins in general represent development and functioning of immune and inflammation system more than expected by chance. Animal studies on the transcriptomic effects of antidepressant treatment, and on chronic social defeat stress, a model of depression, further support the hypothesis that altered immune and inflammatory pathways underlie the etiology and pathophysiology of the disease. Notably, several of the previous meta-analyses or reviews of genomic, transcriptomic and proteomic studies in depression are consistent with this hypothesis. For example, a pathway enrichment analysis of available genome-wide association data on MDD implicated immune system and inflammatory response, besides neurotransmitter and neuronal systems, in the pathophysiological mechanisms underlying depression \[[@R16]\]. Similarly, another pathway based analysis of existing genome-wide association findings revealed that a significant proportion of disease candidate genes are related to inflammatory or immune response \[[@R52]\]. In a separate study of association data on six major neuropsychiatric disorders including MDD, it was found that several of the highly shared genes across disorders are expressed in immune tissues, besides being co-expressed in developing human brain, and implicated in the postsynaptic density \[[@R53]\]. Further, a gene ontology based analysis of available expression profiling data in MDD reported enrichment of innate immune response related processes in genes showing differential expression in hippocampus, not prefrontal cortex and striatum \[[@R54]\]. Although only brain associated transcriptomic and proteomic changes have been reviewed here, it is interesting to note that a recent large scale analysis of gene expression alterations in peripheral blood cells in MDD has identified genes that overrepresent immune pathways previously associated with the disease etiology, clearly supporting the immune hypothesis of depression \[[@R55]\]. Another circulating blood cell transcriptomic study recently provided gene set enrichment based evidence that long-standing depressive symptoms are associated with activated immune-inflammatory pathways \[[@R56]\]. Similarly, proteomic profiling of serum or plasma samples has also revealed altered expression of proteins associated with immunity and inflammation, besides others, in patients with MDD \[[@R57]-[@R60]\]. These findings are consistent with immunological and neurobiological studies on human patients and animal models that increasingly suggest the role of peripheral and central inflammation in depression \[[@R61]-[@R63]\]. Given the emerging interest in anti-inflammatory agents as potential antidepressants \[[@R62], [@R63]\], gene expression analysis in animal models of depression may provide a valuable drug discovery approach for identifying small molecules that modulate immune and inflammatory pathways in the desired direction.
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###### 

Genome-wide association genes in depression overrepresenting immune and inflammation related processes.

  **Immune Response**   **Innate Immune Response**   **Immune System Process**   **Immune System Development**
  --------------------- ---------------------------- --------------------------- -------------------------------
  *ADCY2*               *ADCY2*                      *ADCY2*                     *BCL2*
  *ADCY9*               *ADCY9*                      *ADCY9*                     *CHUK*
  *ATG12*               *ATG12*                      *ATG12*                     *ETV6*
  *BCL2*                *BCL2*                       *BCL2*                      *HDAC9*
  *CAMK2G*              *CAMK2G*                     *CADM1*                     *NOTCH2*
  *CHUK*                *CHUK*                       *CAMK2G*                    *NOTCH4*
  *EGFR*                *EGFR*                       *CHUK*                      *PIK3R1*
  *ENPP1*               *ERBB4*                      *DBH*                       *PLCG2*
  *ERBB4*               *FGF6*                       *DNM2*                      *PPARG*
  *FGF6*                *GRIN2A*                     *EGFR*                      *SYK*
  *GRIN2A*              *HLA-DQA1*                   *ENPP1*                     *TNF*
  *HFE*                 *HLA-DQA2*                   *ERBB4*                     *ZAP70*
  *HLA-DOB*             *HLA-DQB1*                   *ETV6*                      
  *HLA-DQA1*            *HLA-DRA*                    *FGF6*                      
  *HLA-DQA2*            *HSP90B1*                    *GRIN2A*                    
  *HLA-DQB1*            *IFIT1*                      *HDAC9*                     
  *HLA-DRA*             *ITPR1*                      *HFE*                       
  *HSP90B1*             *ITPR2*                      *HLA-DOB*                   
  *IFIT1*               *MAPK1*                      *HLA-DQA1*                  
  *ITPR1*               *PIK3R1*                     *HLA-DQA2*                  
  *ITPR2*               *PLCG2*                      *HLA-DQB1*                  
  *MAPK1*               *PLD2*                       *HLA-DRA*                   
  *PIK3R1*              *PPARG*                      *HSP90B1*                   
  *PLCG2*               *PPP3R1*                     *IFIT1*                     
  *PLD2*                *PRKCA*                      *ITGA1*                     
  *PPARG*               *PRKCE*                      *ITPR1*                     
  *PPP3R1*              *SPTBN1*                     *ITPR2*                     
  *PRKCA*               *SYK*                        *LRMP*                      
  *PRKCE*               *VAV3*                       *MAPK1*                     
  *PVRL1*               *ZAP70*                      *NOTCH2*                    
  *SPTBN1*                                           *NOTCH4*                    
  *SYK*                                              *PIK3R1*                    
  *TNF*                                              *PLCG2*                     
  *VAV3*                                             *PLD2*                      
  *ZAP70*                                            *PMAIP1*                    
                                                     *PPARG*                     
                                                     *PPP3R1*                    
                                                     *PRKCA*                     
                                                     *PRKCE*                     
                                                     *PVRL1*                     
                                                     *RAB8B*                     
                                                     *SIRPG*                     
                                                     *SPTBN1*                    
                                                     *SYK*                       
                                                     *TNF*                       
                                                     *VAV3*                      
                                                     *ZAP70*                     

###### 

Transcriptomic studies reported in human depression.

  **Tissue**                             **Method**                           **Reported Genes\***   **Refs.**
  -------------------------------------- ------------------------------------ ---------------------- ------------
  BA 21                                  Affymetrix HG-U95A arrays            30                     \[[@R23]\]
  Anterior cingulate cortex              Affymetrix HG-U95Av2 arrays          5                      \[[@R24]\]
  Dorsolateral prefrontal cortex         Affymetrix HG-U95Av2 arrays          10                     \[[@R24]\]
  BA 4, 8/9 & 11                         Affymetrix HG-U133 set arrays        50^\#^                 \[[@R25]\]
  Dorsolateral prefrontal cortex         Agilent Human 1A Oligo chip arrays   250                    \[[@R26]\]
  Amygdala, hippocampus, BA 24 & BA 29   Affymetrix HG-U133 set arrays        35^\#^                 \[[@R27]\]
  BA 10                                  Affymetrix HU-95Av2 arrays           100                    \[[@R28]\]
  Mediodorsal nucleus                    Affymetrix HG-U133 Plus 2.0 arrays   30                     \[[@R29]\]
  BA 8/9, 11 & 47                        Affymetrix HG-U133 set arrays        10^\#^                 \[[@R30]\]
  Locus coeruleus                        Affymetrix HG-U133 Plus 2.0 arrays   20                     \[[@R31]\]
  BA 10                                  Affymetrix Exon 1.0 ST arrays        30                     \[[@R32]\]
  Dorsal raphe                           Affymetrix HG-U133 Plus 2.0 arrays   250                    \[[@R33]\]
  Dentate gyrus                          Microarray Inc. HEEBO arrays         15                     \[[@R34]\]
  CA1 pyramidal cell layer               Microarray Inc. HEEBO arrays         15                     \[[@R34]\]
  Hippocampus                            RNA-Sequencing                       3                      \[[@R35]\]

BA, Broadman Area; \*approximate number of differentially expressed genes; ^\#^commonly altered genes in the indicated regions.

###### 

Differentially expressed genes in two or more depression studies overrepresenting immune and inflammation related processes.

  **Immune Response**   **Innate Immune Response**   **Immune System Process**   **Immune System Development**   **Inflammatory Response**
  --------------------- ---------------------------- --------------------------- ------------------------------- ---------------------------
  *FGFR3* (26, 31)      *FGFR3*                      *ANLN* (29, 33)             *ANLN*                          *PIK3C2A*
  *AQP4* (28, 31)       *AQP4*                       *AQP4*                      *BCL6*                          *BCL6*
  *BCL6* (28, 33)       *CHGA*                       *BCL6*                      *SMPD3*                         *CNR2*
  *CHGA* (28, 33)       *ITPR1*                      *CHGA*                      *THRA*                          
  *CNR2* (26, 27)       *LGALS3*                     *CNR2*                                                      
  *ITPR1* (27, 33)      *PIK3C2A*                    *FGFR3*                                                     
  *LGALS3* (28, 29)     *PSMD4*                      *GPM6B* (26, 29)                                            
  *NFIL3* (26, 33)                                   *ITPR1*                                                     
  *PIK3C2A*(27, 30)                                  *LGALS3*                                                    
  *PSMD4* (26, 33)                                   *NFIL3*                                                     
                                                     *PIK3C2A*                                                   
                                                     *PSMD4*                                                     
                                                     *SMPD3* (26, 33)                                            
                                                     *THRA* (28, 33)                                             

###### 

Proteomic studies reported in depression.

  **Tissue**                  **Method**               **No. of Reported Proteins\***   **Refs.**
  --------------------------- ------------------------ -------------------------------- ------------
  Anterior cingulate cortex   MALDI-TOF-MS, LC-MS/MS   15                               \[[@R36]\]
  Cerebrospinal fluid         MALDI-TOF-MS             35                               \[[@R37]\]
  BA 9                        Shotgun LC-MS^\#^        85                               \[[@R38]\]
  BA 9                        Shotgun LC-MS            40                               \[[@R39]\]

BA, Broadman Area; \*approximate number of differentially expressed proteins reported; ^\#^phosphoproteomic analysis

###### 

Transcriptomic studies reporting antidepressant action in animal models.

  **Drug**        **Tissue**               **Treatment Conditions**        **Animal Models**                           **Reported Genes\***   **Refs.**
  --------------- ------------------------ ------------------------------- ------------------------------------------- ---------------------- ------------
  Amitriptyline   Nucleus accumbens        15 mg/kg i.p., 28 days          Male C57Bl/6 mice                           95                     \[[@R40]\]
  Imipramine      Hippocampus              10 mg/kg i.p., 1, 3 or 7 days   Male Sprague-Dawley rats                    25                     \[[@R41]\]
  Fluoxetine      Hippocampus              10 mg/kg i.p., 1, 3 or 7 days   Male Sprague-Dawley rats                    30                     \[[@R41]\]
  Phenelzine      Hippocampus              7 mg/kg i.p., 1, 3 or 7 days    Male Sprague-Dawley rats                    30                     \[[@R41]\]
  Despiramine     Hippocampus              7.5 mg/kg i.p., 21 days         Male Swiss-Webster mice, high-swim stress   70                     \[[@R42]\]
  Despiramine     Hippocampus              7.5 mg/kg i.p., 21 days         Male Swiss-Webster mice, low-swim stress    40                     \[[@R42]\]
  Imipramine      Fronto-temporal cortex   10 mg/kg i.p., 96 h             Sprague-Dawley rats                         3                      \[[@R43]\]
  Imipramine      Fronto-temporal cortex   10 mg/kg i.p., 4 wk             Sprague-Dawley rats                         5                      \[[@R43]\]
  Citalopram      Fronto-temporal cortex   10 mg/kg i.p., 96 h             Sprague-Dawley rats                         10                     \[[@R43]\]
  Citalopram      Fronto-temporal cortex   10 mg/kg i.p., 4 wk             Sprague-Dawley rats                         10                     \[[@R43]\]
  Paroxetine      Hippocampus              10 mg/kg oral, 28 days          Male DBA/2OlaHsd mice                       55                     \[[@R44]\]
  Imipramine      Frontal cortex           10 mg/kg s.c., 7 days           Male Wistar rats, olfactory bulbectomized   230                    \[[@R45]\]

\*approximate number of differentially expressed genes reported in microarray analysis.

###### 

Differentially expressed genes in two or more analyses of antidepressant effects in animal models overrepresenting immune and inflammation related processes.

  **Immune response**          **Innate Immune Response**   **Immune System Process**        **Immune System Development**   **Inflammatory Response**
  ---------------------------- ---------------------------- -------------------------------- ------------------------------- ------------------------------
  *ADM* (41 F, 41 P)           *APP*                        *ADM*                            *CASP8*                         *ADORA1* (41 F, 41 P)
  *APP* (41 F, 41 I, 41 P)     *CASP8*                      *APP*                            *EGR1*                          *PLAA* (41 I, 41 P)
  *CASP8* (41 F, 41 I, 41 P)   *EGR1*                       *CASP8*                          *FAS*                           *SAA4* (41 F, 41 P)
  *EGR1* (44, 45)              *FYN*                        *EGR1*                           *TGFB2*                         *SPP1*
  *ERAP1* (41 F, 41 I, 41 P)   *SNCA*                       *ERAP1*                          *TNFSF11*                       *TAC1* (40, 42)
  *FAS* (41 F, 41 P)           *STX11*                      *FAS*                                                            *TNFAIP6* (41 F, 41 I, 41 P)
  *FYN* (41 F, 41 P)                                        *IGSF6*                                                          
  *IGSF6* (41 F, 41 P, 42)                                  *RAB6A* (41 F, 41 I)                                             
  *SNCA* (41 F, 41 I, 41 P)                                 *SNCA*                                                           
  *STX11* (41 F, 41 I, 41 P)                                *SPP1* (41 F, 41 P)                                              
  *TNFSF11* (41 F, 41 I)                                    *STX11*                                                          
                                                            *TGFB2* (41 F, 41 I, 41 P, 45)                                   
                                                            *TNFSF11*                                                        

Numbers in the parentheses indicate analyses referred in Table **5**, provided for genes at their first column-wise occurrence. F, fluoxetine; I, imipramine, P, phenelzine.

###### 

Transcriptomic studies in rodent models of chronic social defeat stress.

  **Tissue**                 **Animal Model**                **Reported Genes\***   **Refs.**
  -------------------------- ------------------------------- ---------------------- ------------
  Posterior cortex           Male Long-Evans rats, 6 h^\#^   20^@^                  \[[@R46]\]
  Dorsal raphe               Male Wistar rats                2^@^                   \[[@R47]\]
  Frontal cortex             Male Wistar rats                35^@^                  \[[@R47]\]
  Nucleus accumbens          Male C57BL/6J mice, 24 h^\#^    315^@^                 \[[@R48]\]
  Nucleus accumbens          Male C57BL/6J mice, 4 wk^\#^    135^@^                 \[[@R48]\]
  Medial prefrontal cortex   Male C57BL/6J mice              20^\$^                 \[[@R49]\]
  Amygdala                   Male C57BL/6J mice              70^\$^                 \[[@R49]\]
  Ventral hippocampus        Male C57BL/6J mice              55^\$^                 \[[@R49]\]

\*approximate number of differentially expressed genes reported; \*\*indicates reported brain harvestinf time after the end of stress procedure; ^@^indicates microarray analysis; ^\$^indicates RNA sequencing.
